| abstract |
The present disclosure relates to methods and compositions for treating immune-mediated diseases. In some aspects, the present disclosure relates to methods of treating immune-mediated diseases by administering an EHMT2 inhibitor in combination with one or more therapeutic modalities (eg, one or more therapeutic agents). In some aspects, the immune-mediated disease is rheumatoid arthritis, multiple sclerosis, psoriasis, psoriatic disorders, psoriatic arthritis, or inflammatory bowel disease. |